Thus, to obtain a more sensitive and precise estimate of the number of T/F viruses that were responsible for productive clinical infection in these very high-risk subjects, we performed TDS at the earliest AHI samples (i.e., from the first positive NAT through peak viremia). This evidence concerns the gene BRD2 and infection.